RE:RE:RE:RE:RE:RE:RE:RE:RE:PresentationBio you can check the value of peers all you want Semma was bought out for 950mil US preclinical around 1.3mil Can it will not change. SGTX has had valuations up to almost 2b but they are also preclinical and simply do not have the science to back it up, some stagnation and retracement is only natural. In the meantime Sernova is well into clinical trials w/ very positive results and likely to see multiple indications in the clinic soon. Grasping at straws trying to understand what's going on behind the NDAs does no one any service. Fact is you are making assumptions. None of us know where big pharma stands in current negotiations and that wild card remains a real possibility.
Re: changing the board. Who do those that are so quick to act have in mind as a replacement?